Early detection of tuberculosis (TB) is essential to improve health outcomes for people with TB, and to reduce TB transmission more effectively. Systematic screening in high risk groups is a complement to efforts to improve the patient-initiated pathway to TB diagnosis (that is, diagnosing TB among peopl...
The overall objective of the guidelines is to provide public health approach guidance on evidencebased practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. The guidelines are expected to provide the basis and rationale for the developmen...
The objective of this guideline is to provide recommendations on the intake of free sugars to reduce the risk of NCDs in adults and children, with a particular focus on the prevention and control of unhealthy weight gain and dental caries. The recommendations in this guideline can be used by policy-make...
Medicines account for 20–60% of health spending in low- and middle-income countries, compared with 18% in countries of the Organisation for Economic Co-operation and Development. Up to 90% of the population in developing countries purchase medicines through out-of-pocket payments, making medicines the ...
Tests based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in urine have
emerged as potential point-of-care tests for tuberculosis (TB). LAM antigen is a lipopolysaccharide
present in mycobacterial cell walls, which is released from metabolically active or degenerating
bacterial cells ...
The Consolidated guidelines on HIV testing services bring together existing guidance relevant to the provision of HIV testing services (HTS) and addresses issues and elements for effective delivery of HTS that are common in a variety of settings, contexts and diverse populations. In addition, this docume...
Early detection of tuberculosis (TB) is essential to improve health outcomes for people with TB, and to reduce TB transmission more effectively. Systematic screening in high risk groups is a complement to efforts to improve the patient-initiated pathway to TB diagnosis (that is, diagnosing TB among peopl...
In 2011 WHO conditionally recommended the use of at least 36 months of isoniazid preventive therapy (IPT) (as a proxy for lifelong or continuous treatment) for people living with HIV in high TB-prevalence and transmission settings. The evidence of the benefits and harms of 36-month IPT compared to 6-mont...
In 2015 WHO updated the mhGAP guidelines, first issued in 2009, for the management of mental, neurological and substance use (MNS) disorders. In order to reduce the gap and to enhance the capacity of Member States to respond to the growing challenge, the World Health Organization (WHO) developed the Ment...
This early-release guideline makes available two key recommendations that were developed during the revision process in 2015. First, antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Second, the use of daily oral pre-exposure prophylaxis (PrEP) is recomme...
